IntelliGenome Appoints SIMED as Exclusive Distributor for CRISPR-TB™ in Peru and Ecuador
IntelliGenome Appoints SIMED as Exclusive Distributor for CRISPR-TB™ in Peru and Ecuador
PR Newswire
HOUSTON and QUITO, Ecuador, Sept. 8, 2026
HOUSTON and QUITO, Ecuador, Sept. 8, 2026 /PRNewswire/ -- IntelliGenome, Inc. today announced the appointment of SIMED S.A. as its exclusive distributor for the CRISPR-TB™ Blood Test in Peru and Ecuador.
IntelliGenome received DIGEMID registration approval for the CRISPR-TB Blood Test in Peru, enabling commercial distribution in one of the region's most important tuberculosis markets. Under the new partnership, SIMED will initiate the product registration process in Ecuador.
CRISPR-TB is an innovative molecular blood test that detects circulating Mycobacterium tuberculosis cell-free DNA, representing a novel non-sputum approach to tuberculosis detection.
SIMED was selected for its strong expertise in tuberculosis diagnostics, molecular laboratory solutions, and established relationships with hospitals, reference laboratories, and public health institutions throughout Peru and Ecuador.
"SIMED combines deep tuberculosis expertise with one of the region's strongest molecular diagnostics organizations, making them an ideal partner to accelerate adoption of CRISPR-TB across Peru and Ecuador," said Kurt Wehrle, Vice President, Partnerships & Strategic Alliances at IntelliGenome.
The partnership significantly expands IntelliGenome's commercial presence in Latin America while strengthening SIMED's tuberculosis diagnostics portfolio with an innovative blood-based molecular technology.
"CRISPR-TB is an important addition to our tuberculosis diagnostics portfolio and reinforces our commitment to bringing innovative molecular technologies to laboratories throughout Peru and Ecuador." said Abelardo Cruces, General Laboratory and Biosciences Business Manager at SIMED.
About IntelliGenome
IntelliGenome, Inc. is a molecular diagnostics company focused on the development and commercialization of innovative CRISPR-based diagnostic technologies. The company's CRISPR-TB™ platform utilizes proprietary molecular detection technologies to identify tuberculosis from blood samples and is being evaluated globally through collaborations with clinical, academic, and public health partners. IntelliGenome is advancing both laboratory-based and near-patient testing solutions to expand access to tuberculosis diagnostics worldwide.
About SIMED
Founded in 1985, SIMED S.A. is one of the leading providers of diagnostic, laboratory, and life science solutions in Peru and Ecuador. Through long-standing partnerships with many of the world's leading healthcare companies, SIMED supports hospitals, public health institutions, clinical laboratories, and research organizations with advanced technologies and specialized technical expertise.
Media Contact:
Kurt Wehrle
Vice President, Partnerships & Strategic Alliances
IntelliGenome, Inc.
422138@email4pr.com
Mobile: (847)542-1542
SOURCE IntelliGenome
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States